Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07, ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

Merus expects the FDA to make a decision on the application in February after reviewing additional manufacturing information it submitted.

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab ...

Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.